Latest Medicinal Cannabis News

Page 6 of 8
Althea Group Holdings announces the immediate resignation of founder and CEO Joshua Fegan, appointing Barry Katzman as interim CEO to steer the company’s THC beverage growth in North America.
Victor Sage
Victor Sage
24 July 2025
Bioxyne Limited reports a record-breaking Q4 FY25 with revenue soaring 204% year-on-year and a strategic entry into the German market through a €3.2 million manufacturing agreement.
Victor Sage
Victor Sage
24 July 2025
Little Green Pharma reported a robust June 2025 quarter with record cash receipts and expanding European footprint, highlighted by a new production capacity in Denmark and the launch of its CherryCo brand in Germany.
Ada Torres
Ada Torres
17 July 2025
ECS Botanics is supplying its Avani THC10 capsules to a University of Western Australia clinical trial exploring medicinal cannabis as a treatment for obstructive sleep apnoea. The study aims to shed light on THC’s impact on sleep quality and cognitive function.
Ada Torres
Ada Torres
7 July 2025
ECS Botanics has launched the globally acclaimed Terphogz™ cannabis strains, including The Original Z™, into the Australian medicinal market, marking a strategic expansion of its premium product portfolio.
Ada Torres
Ada Torres
30 June 2025
Bioxyne Limited, through its subsidiary Breathe Life Sciences, has secured a significant supply agreement to enter Germany’s burgeoning medical cannabis market, promising at least A$5.6 million in revenue for FY2026.
Victor Sage
Victor Sage
18 June 2025
Bioxyne Limited's subsidiary Breathe Life Sciences has achieved key GMP certifications across multiple international markets, paving the way for expanded operations in Europe, the UK, Canada, and Singapore. The company signals strong growth prospects for FY2026, with formal guidance expected in August.
Victor Sage
Victor Sage
18 June 2025
Bioxyne Limited has raised its FY2025 revenue guidance to $28 million, driven by explosive growth in Australian pharmaceutical manufacturing and the upcoming commercial production of MDMA capsules. The company is also making strides in expanding its footprint across Europe.
Victor Sage
Victor Sage
12 June 2025
Little Green Pharma invites shareholders to a detailed FY2025 financial results webinar, promising insights into profitability, revenue growth, and recent financing achievements.
Ada Torres
Ada Torres
10 June 2025
Cann Group Limited has resolved its legal dispute with Rua Biosciences, paving the way for new commercial agreements to supply medicinal cannabis products across Australia and New Zealand.
Ada Torres
Ada Torres
4 June 2025
Little Green Pharma Ltd has reported a robust turnaround for FY2025, posting a $3.3 million profit after tax on revenues up 43%, driven by strong growth in Australia and Europe and strategic acquisitions.
Ada Torres
Ada Torres
30 May 2025
Cann Group Limited has reported a strong operational update, exceeding its medicinal cannabis production targets and significantly reducing costs, while expanding sales channels and securing fresh capital to bolster its balance sheet.
Ada Torres
Ada Torres
30 May 2025